Mir S Adil1, M Amer Khan2, M Nematullah Khan2, Ihtisham Sultan2, M Aamer Khan2, S Amir Ali3, Afroze Farooqui2. 1. Deccan School of Pharmacy, Clinical Pharmacist, Apollo Hospital , Jubilee Hills, Hyderabad, India . 2. Student, Deccan School of Pharmacy , Hyderabad, India . 3. Head of Department, Department of Pharmacy Practice, Owaisi Hospital & Research Centre , Hyderabad, India .
Abstract
INTRODUCTION: Inappropriate drug usage may preclude ideal benefit due to increased medical cost, antimicrobial resistance, adverse effects and mortality. Therefore drug utilization studies have become a plausible means in evaluating the healthcare systems. COPD management usually involves more than one drug which may escalate the risk of ADEs (adverse drug events). AIM: The present study was aimed at assessing the current drug practice and ADEs in COPD management in ICU. MATERIALS AND METHODS: A total of 1,044 patients admitted for the treatment of COPD were included in the study. Their prescriptions were recorded for evaluation of drug utilization and patients were counseled for assessing ADEs. Results were evaluated by Chi-square test and percentages. RESULT: All-embracing 15,360 drugs were prescribed at an average of 14.71 drugs per patient, wherein β2-agonists were extensively prescribed agents followed by inhaled-corticosteroids and anti-cholinergics. 372 ADEs were reported in 252 patients, wherein restlessness was the most frequent ADE and theophylline was found to be associated with highest cases of ADEs. CONCLUSION: Practitioners should prescribe least number of drugs to mitigate the likelihood of adverse outcomes in patients due to numerous drugs usage, which may be achieved by following GOLD guidelines. The present work may help in improving the current management of COPD by rectifying the flaws delineated in this article.
INTRODUCTION: Inappropriate drug usage may preclude ideal benefit due to increased medical cost, antimicrobial resistance, adverse effects and mortality. Therefore drug utilization studies have become a plausible means in evaluating the healthcare systems. COPD management usually involves more than one drug which may escalate the risk of ADEs (adverse drug events). AIM: The present study was aimed at assessing the current drug practice and ADEs in COPD management in ICU. MATERIALS AND METHODS: A total of 1,044 patients admitted for the treatment of COPD were included in the study. Their prescriptions were recorded for evaluation of drug utilization and patients were counseled for assessing ADEs. Results were evaluated by Chi-square test and percentages. RESULT: All-embracing 15,360 drugs were prescribed at an average of 14.71 drugs per patient, wherein β2-agonists were extensively prescribed agents followed by inhaled-corticosteroids and anti-cholinergics. 372 ADEs were reported in 252 patients, wherein restlessness was the most frequent ADE and theophylline was found to be associated with highest cases of ADEs. CONCLUSION: Practitioners should prescribe least number of drugs to mitigate the likelihood of adverse outcomes in patients due to numerous drugs usage, which may be achieved by following GOLD guidelines. The present work may help in improving the current management of COPD by rectifying the flaws delineated in this article.
Authors: L Gallelli; G Ferreri; M Colosimo; D Pirritano; M A Flocco; G Pelaia; R Maselli; G B De Sarro Journal: Pharmacol Res Date: 2003-06 Impact factor: 7.658
Authors: Berendina M Roede; Patrick Je Bindels; Henk J Brouwer; Paul Bresser; Corianne Ajm de Borgie; Jan M Prins Journal: Br J Gen Pract Date: 2006-09 Impact factor: 5.386
Authors: Ken Ohta; Yoshinosuke Fukuchi; Lawrence Grouse; Ryuji Mizutani; Klaus F Rabe; Stephen I Rennard; Nan-Shan Zhong Journal: Respir Med Date: 2004-10 Impact factor: 3.415